Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Kappos, Ludwig; Gold, Ralf; Miller, David; MacManus, David; Havrdova, Eva; Limmroth, Volker; Polman, Chris; Schmierer, Klaus; Yousry, Tarek; Yang, Minhua; ERAKSOY, Mefküre; Meluzinova, Eva; Rektor, Ivan; Dawson, Katherine; Sandrock, Alfred; O'Neill, Gilmore

doi:10.1016/s0140-6736(08)61619-0

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Copy For Citation

Kappos L., Gold R., Miller D. H., MacManus D. G., Havrdova E., Limmroth V., ...More

LANCET, vol.372, no.9648, pp.1463-1472, 2008 (SCI-Expanded)

Publication Type: Article / Article
Volume: 372 Issue: 9648
Publication Date: 2008
Doi Number: 10.1016/s0140-6736(08)61619-0
Journal Name: LANCET
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1463-1472
Istanbul University Affiliated: No

Abstract

Background Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis.